Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

Vertex Pharmaceuticals Inc. closed $106.51 short of its 52-week high ($519.88), which the company reached on November 8th.

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...

In a report released today, Gena Wang from Barclays maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price ...

In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

Vertex Pharmaceuticals (VRTX) closed at $409.56 in the latest trading session, marking a -0.62% move from the prior day.

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.

International Assets Investment Management LLC lowered its position in shares of Vertex Pharmaceuticals Incorporated ...

ORG Partners LLC boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 108.2% ...